Reported findings of elevated risk of adverse events associated with calcium channel blocker use in hypertensives may be due partly to unmeasured confounding by indication. To determine if such confounding occurs, we conducted a retrospective cohort analysis of 77 196 Pennsylvania Medicaid recipients aged 18 to 61 who were treated with antihypertensive medication between 1990 and 1992. All diagnoses and dispensed prescriptions during the year prior to study entry were examined. Prior recipients of multitherapy (n ‫؍‬ 18 763) were more likely to have had previously diagnosed risk factors (OR ‫؍‬ 1.31 [95% CI, 1.30-1.33]) than subjects with prior monotherapy (n ‫؍‬ 11 141). New initiators (n ‫؍‬ 47 292) were less likely to have had previously diagnosed risk factors (OR ‫؍‬ 0.48 (95% CI, 0.47-0.49)) than previous users (n ‫؍‬ 29 904). The likelihood of being prescribed calcium channel blocker rather than other monotherapy was significantly higher for subjects diag-
Introduction
In 1995, physicians and hypertensive patients were alarmed by press reports of a case control study 1 and a prospective observational study 2 which found elevated risks of cardiovascular events and death associated with use of calcium channel blockers (CCB) to treat hypertension.
The ensuing controversy has not been quieted either by the FDA's review of the evidence and conclusion that no labeling changes were needed for CCB approved for this indication or by the report by the Liaison Committee of the World Health Organi-zation and the International Society for Hypertension (WHO/ISH, hereafter). The WHO/ISH review of the evidence concluded that observational studies are vulnerable to systematic bias due to possible confounding by indication. The committee concluded that, 'It is possible, indeed likely, that the decision to prescribe a calcium antagonist specifically for the treatment of high blood pressure was frequently determined, at least in part, by factors associated with CHD [cardiovascular heart disease] risk (such as disease history, age, risk factor levels). Thus the use of hypertensive patients as controls will not necessarily avoid confounding by indication'. 3 To evaluate the possibility that confounding does occur, a retrospective cohort study was conducted in a population of Pennsylvania Medicaid users of antihypertensive medications. The purpose of this study was to demonstrate the existence of confounding by indication in hypertension by measur-ing the correlation between known risk factors for serious cardiovascular events and history of pharmacotherapy exposure over time and by drug class(es). We tested the following hypotheses:
(1) New initiators of drug therapy for hypertension differ from those with prior drug therapy in terms of key cardiovascular and other comorbid conditions (diabetes, COPD) and disease severity; (2) Patients previously treated with multiple classes of drugs indicated for hypertension and angina differ from those treated with monotherapy and from new initiators of drug therapy in terms of their relevant comorbidity and severity; (3) Patients previously treated with CCB monotherapy represent a more severely ill patient group than those given other classes of monotherapy; (4) Accurate measurement of duration and class(es) of prior drug treatment must be based on at least a 12-month window of time.
Confirmation of these hypotheses would support the conclusion that duration, classes and combinations of antihypertensive pharmacotherapy are associated with pre-existing cardiovascular risk factors and that the reported association of CCB to myocardial infarction may be due, in part, to selective prescribing to patients at higher risk and, therefore, to confounding by indication.
Materials and methods

Data source
We used administrative data on paid claims from Pennsylvania's Medicaid Management Information System to extract detailed diagnostic, demographic, eligibility, and health care utilisation data for the study population. This is the nation's fifth largest Medicaid programme, annually enrolling more than 1. 
Study drugs: prescribing and baseline analysis
We extracted and arrayed in chronologic order subjects' medical and prescription claims for services provided during the 12 months prior to their index date to understand their baseline medical and medication history. Study drug classes included all that are indicated for the treatment of hypertension and/or angina: ACE inhibitors, adrenergenic blockers selected adrenergic stimulants (eg, clonidine), alpha/beta-blockers, beta-blockers, CCBs, diuretics, rauwolfia, and vasodilators. We identified new initiators of study drugs vs those who filled at least one prescription for a study drug in the baseline year. We also identified the classes and combinations of baseline prescriptions dispensed to subjects.
To characterise baseline health status in terms of known cardiovascular risk factors, we identified subjects with the presence of at least one claim with each of the following 13 ICD-9 coded diagnoses: hypertension (ICD-401, 401.0, 401.1, 401. For subjects with these diagnoses, we ascertained the utilisation of medical ser-vices in the baseline period overall and by type of service used (outpatient, emergency room, or inpatient). Volume of claims for treatment for these conditions, especially hospitalisation, was used as a proxy for disease severity.
Classifying study subjects by medication history
The entire study population was first classified into two study cohorts-those who were new users of study drugs and those who had previously used study drugs during the baseline period. Previous users were further subcategorised into those who had received more than one class of study drugs and those who had only received monotherapy during their baseline period. Monotherapy recipients were categorised by the class of study drug they had received. Demographic and baseline health status measures (diagnosis of each risk factor, the number of diagnoses, and the use of medical services for the treatment of a diagnosis) were then estimated separately for the new and previous users as well as for the prior users of monotherapy vs multitherapy.
Statistical tests of significance were conducted to evaluate the differences between new and previous users of drug therapy and between subgroups of the latter in terms of demographics and baseline measures of health status. We used chi-square tests of association where appropriate to determine the significance of differences in incidence measures. For the continuous variables, tests of normality were performed and non-parametric, Wilcoxon, rankorder tests of differences in medians (rather than ANOVA methods) were used wherever the hypothesis of non-normality could not be rejected. In evaluating differences across drug groups in terms of association with presence of any of the comorbid conditions, number of comorbidities or associated health care utilisation at baseline, the 95% level of significance (P Ͻ 0.05) was used. However, while evaluating differences across drug groups in terms of each of the 13 separate baseline conditions, an adjustment for multiple comparisons was made by using (P Ͻ (0.05/13) ie, P Ͻ 0.004 as a criterion for determining statistical significance in individual tests. We also performed logistic regression analysis to evaluate the association between each prior diagnosis and subsequent (no more than 7 days later) dispensing of CCB monotherapy, after controlling for age, gender, race, and other diagnoses. Selection of CCB monotherapy was the dependent variable in the multivariate analysis. While the resulting adjusted odds ratios are reported here, we also approximated the adjusted risk ratio (RR) from the adjusted odds ratio because the events of interest are not rare. We used the formula:
where OR is the adjusted odds ratio and Po is the prevalence of the diagnosis in the non-CCB group. 5 
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Results
Patient demographics
The total study population consisted of 77 196 Pennsylvania Medicaid recipients who satisfied all of the eligibility requirements for study entry. As expected, subjects were predominantly female (72.3%) and disproportionately black (32.1%). The complete demographic profile of the study population is contained in Table 1 .
Of the total study population, 61.3% (47 292 patients) did not fill a prescription for a study drug in the baseline year while the remaining 38.7% (29 904) did fill at least one such prescription during their baseline. Among the prior users of study drugs, only 25% filled a prescription 30 days prior to their index date and about 60% filled a prescription within 60 days prior to their index date. An important finding is that it was essential to examine the entire year prior to the index date in order to account for the baseline medication history of the cohort of previous users. Failure to use this extensive search strategy would have resulted in misclassification of subjects' exposure to study drugs.
New vs prior users of study drugs differed demographically: previous users of study drugs were significantly older on average (48.1 years) than new initiators of drug therapy. Second, the percentage of patients who were female was slightly but statistically significantly greater among previous users of study drugs compared with new initiators. Third, the proportion of patients who were black was significantly greater among previous users of drug therapy (Table 1) .
Baseline health status and use of medical services
The baseline health status of study subjects was evaluated in terms of the total number of diagnosed comorbidities on average as well as the existence of specific diagnoses. Further, we compared new and previous study drug users in terms of these measures of health status to test the hypothesis that previous use of study drugs correlates with a greater number of existing comorbidities in general. We further compared differences in baseline health measures between users of monotherapy and multiple classes of study drugs to examine the hypothesis that existence of diagnosed comorbidities is associated with a more complex pattern of medication prescribing for these drugs. Finally, we examined the association between CCB monotherapy versus other monotherapy classes and diagnoses recorded up to seven days before the first baseline prescription was dispensed.
We found that new users of study drugs were less likely to have had at least one prior comorbidity (OR = 0.48 [95% CI, 0.47-0.49]) than previous users. When we evaluated baseline health status in terms of specific diagnoses, new initiators of study drugs were significantly (P = Ͻ0.004) less likely than prior users to have a prior year diagnosis of the following conditions: angina, AMI, arteriosclerotic cardiovascular disease, congestive heart failure, hyperlipidaemia, hypertension, ischaemic heart disease, stroke, COPD, or diabetes ( Table 2) .
The comparisons of previous users and new initiators of drug therapy in terms of the frequency with which they used medical services to treat these conditions are presented in Table 2 . Because the underlying distributions of the number of claims for medical services were found not to be distributed There were no diagnoses of cardiac dysrhythmia, cardiomyopathy, conduction disorders, or hypertensive renal disease among the patients with no cardiovascular study drugs in the prior year. Among patients who did use cardiovascular study drugs in the prior year, one patient had a diagnosis of cardiomyopathy, one patient had a diagnosis of cardiac dysrhythmia, and two patients had a diagnosis of hypertensive renal disease. Differences in incidence rate of these conditions across cohorts were not significant. Chi-square tests of differences in incidence were used. b Kruskal-Wallis (or equivalent Wilcoxon rank-sum) tests of differences in the median number of claims were used. *Significantly different from cohort with no prior year study drugs at P Ͻ 0.004 (multiple-comparison adjusted level of significance). **Significantly different from CCBs at P Ͻ 0.0001.
normally, non-parametric (Wilcoxon, rank-order) tests of differences in the medians were used. The differences were again striking ( Table 2) . Those who had used study drugs in the baseline year had significantly (P Ͻ 0.004) greater number of claims for ambulatory and inpatient medical services compared to new initiators of therapy for all of the examined conditions. Of the 29 904 previous users of study drugs, 11 141 only used a single class of drugs during the baseline period while the remainder used multiple classes of drugs. Prior users of multitherapy were more likely to have had at least one of the prior comorbidities (OR = 1.31 [95% CI, 1.30-1.33]) than prior users of monotherapy. Further, the multitherapy group was more likely to have had prior year diagnoses of angina, AMI, arteriosclerotic cardiovascular disease, congestive heart failure, COPD, diabetes, hypertension, ischaemic heart disease, and stroke relative to the monotherapy group (P Ͻ 0.004).
Finally, based on the non-parametric tests of differences in medians, the multiple therapy subgroup had significantly (P Ͻ 0.004) greater number of claims for medical services to treat the following conditions: angina, congestive heart failure, hypertension, and ischaemic heart disease.
Baseline health status and use of specific classes of monotherapy
Among the 11 141 patients prescribed monotherapy in the baseline period, 1703 patients only received a CCB. They were compared to patients with other classes of monotherapy: beta-blockers (2684), diuretics (4188), ACE inhibitor (1458) and all 9438 patients prescribed any non-CCB monotherapy. The CCB group had significantly more comorbidities (P Ͻ 0.05) than the comparator groups (Table 3) . Further, the CCB group had a significantly (P Ͻ 0.004) greater proportion of patients diagnosed with each of the comorbidities except hyperlipidaemia compared to the beta-blocker group. Compared Evaluation of median differences is based on Kruskal-Wallis (or equivalent Wilcoxon rank-sum) tests.
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to the diuretics-only group, the CCB group had a significantly greater percentage of patients with each of the comorbidities except congestive heart failure, COPD, and hyperlipidaemia. As seen in Table 3 , prior-year use of diuretics was associated with prior diagnosis of congestive heart failure when compared to prior use of CCBs (P Ͻ 0.004). Because diuretics are specifically indicated for congestive heart failure, it is not surprising that this diagnosis was strongly associated with the drug class. When compared to the ACE inhibitor group, the CCB group was associated with prior diagnosis of all conditions except congestive heart failure, hyperlipidaemia, and stroke. When compared to non-CCB monotherapy as a whole, the CCB group had a greater proportion of patients with each diagnosed condition of interest except congestive heart failure and hyperlipidaemia.
We examined frequency of use of medical services across the specific monotherapy drug classes (Table 3 ). Patients treated with CCBs had significantly more claims on average for all diagnosisrelated medical services than patients on diuretics, beta-blockers, or all non-CCB monotherapy (P Ͻ 0.05). As a further test of the underlying differences in severity between patients prescribed calcium channel blockers and those prescribed other monotherapies, we examined the incidence of hospitalisation for each of the conditions of interest. Although the percentage of patients hospitalised for any of the study conditions was relatively small, there were some differences across study treatment groups, albeit not in comparing the CCB group to the beta-blocker group. The proportion of patients who had inpatient hospital claims for any of the individual conditions considered was not significantly different among the CCB group relative to the beta-blocker group, adjusting for multiple comparisons (P Ͼ 0.004).
However, when compared to the diuretics group and all other types of monotherapy, a significantly higher percentage of CCB patients were hospitalised for hypertension and diagnoses other than those specifically considered in this study (P Ͻ 0.004).
Next, we restricted our analyses to diagnoses recorded 7 days or less prior to the date on which the first baseline study drug was dispensed. The adjusted odds ratios of being prescribed CCBs rather than other monotherapy for each of the baseline conditions were estimated. The adjusted odds of being prescribed a CCB were significantly higher among those with prior diagnoses of arteriosclerotic cardiovascular disease (OR = 7.78 (P Ͻ 0.0001)); angina (OR = 2.92 (P Ͻ 0.0001)); diabetes (OR = 1.49 (P = 0.0004)); and hypertension (OR = 1.57, (P Ͻ 0.0001)). When we converted the adjusted odds ratios to adjusted relative risks, the direction of the results remained unchanged.
Discussion
Our results show that medication history correlates closely with cardiovascular conditions and relevant comorbidities such as COPD and diabetes. More importantly, the results show that prior-year medication history can be used to predict not only the presence of these comorbidities, but also the severity of these conditions, as measured by the volume of related medical services, including hospitalisation.
We examined two aspects of medication history: (1) duration measured by current use only versus past use of study medications, (2) and classes and combinations of prior medications. Duration of use of study drugs was strongly associated with the diagnosis of both more conditions and specific cardiovascular conditions. A similar association was observed for use of multiple drug classes compared to use of monotherapy. Finally, use of CCB monotherapy was associated with more prevalent diagnoses of known cardiovascular risk factors except congestive heart failure.
Our finding that CCB are selectively prescribed for patients at higher risk cannot be generalised beyond this large indigent population and should be replicated elsewhere.
Some have argued that the non-randomised classification of subjects into various exposure groups in observational studies would not pose a serious bias due to confounding by indication if there was sufficient variation in the prescribing habits of physicians to ensure a de facto randomisation of patients. 6 However, our findings suggest that CCBs are selectively prescribed for patients at higher risk and that there is potential for confounding by indication. The degree to which confounding by indication introduces bias is a function of the prevalence of the confounding condition(s), the association of these conditions with outcomes and the systematic variation of prevalence of the conditions with category or class of medication exposure. 7, 8 The potential for bias due to confounding by indication may be eliminated or minimised by restricting an observational study of pharmacologic treatment to newly diagnosed subjects, with minimal comorbidity. 9 In more general populations, it may be necessary to statistically adjust for the underlying severity of disease at baseline. However, the information required to adequately capture all prognostic and symptomatic factors considered by the prescribing physician is not likely to be found in administrative claims databases. The 1-year medication history can be a useful proxy for severity with administrative-claims data based studies. Indeed, one study found that the measured relative risk did vary by the window of time used to ascertain medication history, albeit insignificantly on account of limited power to detect such differences. 10 Observational studies can be a valid and economical way to assess the long term safety and effectiveness of antihypertensive medications provided that the study design minimises indication bias. 11 We have found that examining at least 1 year of medication history, observing switches in therapy, and carefully distinguishing among types of drug therapy are important for the prediction of underlying risk status of patients with hypertension and/or angina, and may reduce, if not eliminate potential for bias produced by confounding by indication. These findings based on Medicaid claims data should be re-examined in other payor settings.
